Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 182.50 180.00 185.00 182.50 182.50 182.50 1,967 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 289

Amryt Pharma Share Discussion Threads

Showing 4901 to 4918 of 5775 messages
Chat Pages: Latest  207  206  205  204  203  202  201  200  199  198  197  196  Older
DateSubjectAuthorDiscuss
29/8/2019
23:29
mdalos1 29 Aug '19 - 21:47 - 4773 of 4773 0 0 0 approx. 2/3rds of the US Business's debt gets written off but Shareholders in that failing Business end up with approx. 2/3rds of the new AMRYT, whilst carrying over approx. 1/3rd of their current/original debt. They (the US) like the look of what we may have (tbc) and are using us as an instrument to reinvent themselves in order to write-off a large chunk of their own Business failings. We're being acquired, the real Investors/Financial Institutes orchestrating matters are offering a brief Premium to us as part of their takeover of us and a "Carrot" to stay put for the medium-term. Lots of (RTO) smoke & mirrors, for sure... and (our) AP101 is just the gamble it's always been. p.s. There's more to the CVR arrangements than what you've gleaned from that RNS AND what you've posted is actually NOT supportive of what you're claiming either, if you read what you've written !! You need to read your Shareholder Pack and the specifics of the lengthy CVR section >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> But, mdalos, by your own figures the new AMYT will have only 1/3rd of the debt that Aegerion had and still have that circa US$130m (revenue for 2018) Aegerion revenue from Juxtapid and Myalept sales to service that much reduced debt, plus the revenue from Lojuxta. That Aegerion debt totalled US$446.6 (though that was reduced after 2018 ended according to the Novelion a/c's). Even if it was US$446.6m by your figures that would be reduced by 2/3rds to US$147m after the takeover. With a possible US$150m+ turnover in 2019 they should be able to service that debt by paying the annual interest bill on that US$147m debt (and maybe paying off some of the outstanding debt?). The annual interest bill is likely to be much less than US$30m on US$147m. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> "We're being acquired" >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> We all know that mdalos. It's an RTO. AMYT is being used as the RTO vehicle rather like FAST was the RTO vehicle used to list Amryt. As I've said before, mdalos, I'm only a tiny shareholder and I'm prepared to wait for the Nasdaq listing and see how the Americans value AMYT. When that happens I will make up my mind whether to sell. Just like you in fact!
papillon
29/8/2019
21:46
mdalos1 29 Aug '19 - 20:39 - 4770 of 4771 0 0 0 The whole CVR situation looks like an enticing medium-term offer, designed to lock people in for another 2-3 years... but could so easily amount to nothing too. There's a lot of Aegerion's debt being taken via swings & roundabouts and the reformed (new) Amryt HAS to make regular quarterly interest payments from the get go. It looks for all the world as though this is designed to give the impression that (old) Amryt's potential Products might actually come to something (the carrot to stay with and agree the arrangements) whilst the actual nearer-term reality is one of large Debt for (new Amryt) and very significant benefits to US Creditors. If the actual share price of our actual new Shares actually do what I expect them to do in the short-term, particularly should a NASDAQ listing complete, I will be off & away with me loot. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> "The whole CVR situation looks like an enticing medium-term offer, designed to lock people in for another 2-3 years... but could so easily amount to nothing too." But mdalos once you have your CVRs you don't have to be locked into your new AMYT shares to benefit from AP101 (assuming it's successful) in the future. You can sell them and still retain your CVRs. Here's what yesterday's RNS states: "Contingent Value Rights ("CVRs") Shareholders in Amryt, on the CVR Record Date, will (conditional on closing of the Transaction occurring) receive CVRs pursuant to which up to $85 million may become payable to Amryt's existing Shareholders and Option holders if certain approval and revenue milestones are met in relation to one of Amryt's principal products, AP101. The CVR Record Date is 20 September 2019. If Shareholders sell their Ordinary Shares in advance of the CVR Record Date they will not be entitled to receive CVRs. The value of these CVRs is up to US$1.48 per Ordinary Share (GBP1.22 based upon an exchange rate of GBP1:$1.21)." >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> "If the actual share price of our actual new Shares actually do what I expect them to do in the short-term, particularly should a NASDAQ listing complete, I will be off & away with me loot." It's never wrong to take a profit, mdalos, so your stratagem could well be the correct one. ATB whatever you do.
papillon
29/8/2019
21:21
Most of the debt has been effectively written off (hence the bond holder action). It was the debt that sunk them in the 1st place.
waterloo01
29/8/2019
19:59
The AMYT story has just begun. I’m holding for the foreseeable
volsung
29/8/2019
19:16
mdalos1 29 Aug '19 - 16:29 - 4764 of 4767 0 0 0 Could be sometime January, maybe earlier but it won't be September, nor October, nor November, possibly Xmas !! I expect I'll be long gone sometime this Autumn, unless some sort of factually trustworthy revelation occurs before December that encourages me to hold "long". >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>. Whatever will be, will be, mdalos. No more dodgy analysis from me! I've learnt my lesson! At least AMYT shares are tradeable again after being suspended for around 3 months. If I wanted to I could sell my shares now having made a bit more than 30% profit, but I'll stick around and will add a few more before the 20th September provisional CRV deadline. I've only gambled money I can afford to lose. Perhaps Ray Stafford is so rich he has only gambled money (£827k) he can afford to lose, but I have my doubts. His large personal investment gives me confidence in the future; after all he is an AMYT insider whereas we are all outsiders. This AMYT/Aegerion takeover saga reads like a thriller where the reader has to wait until the final chapter to find out the outcome.
papillon
29/8/2019
18:37
I'd really like to see some independent analysis of the combined entity. I hope it will make illuminating reading, as and when one gets done.
waterloo01
29/8/2019
18:06
There are plenty of references to the planned Nasdaq listing in the doc on Amryt.com
alphabravo321
29/8/2019
16:38
That's how I read it papillon
webpax
29/8/2019
16:04
I presume, webpax, that the "within 90 days of closing" refers to within 90 days of the Aegerion takeover being closed? In other words within 90 days of the 24th September, the provisional date for the AEgerion takeover deal to be finalised? tia
papillon
29/8/2019
15:35
"Pursuant to the agreement, New Amryt will apply to list its ordinary shares, or American depositary shares representing New Amryt Shares, on Nasdaq within 90 days of Closing. "
webpax
29/8/2019
15:13
Thanks waterloo01. I'll have a look. I was trying to be too clever by half with my earlier post (I deleted the nonsense I posted). I was looking for a motive that wasn't there! I hope I'm not getting senile in my old age! Or worse still becoming a conspiracy theorist! LOL. I don't want to end up in the looney bin in the next bed to mdalos! Only joking, mdalos! The share price is holding up well. I will continue to hold and may add a few more before the CRV cut off date of 20th September. I can't predict the future, but I'm sure it's a good gamble and currently one of the better AIM gambles. I wouldn't mind holding between 5000 and 6000 shares by the 20th September. We've had 3 placings so far. The initial one at 24p, then the one in September 2017 at 20p and now this latest one at the equivalent price of 15p (90p after consolidation). Hopefully the next promised placing at the equivalent price of 24.66p (148p after consolidation) augurs well for the future as it will reverse the downward trend in placing prices.
papillon
29/8/2019
14:02
It' all downloadable on their website.
waterloo01
29/8/2019
13:43
My shares are held in a broker nominee a/c, mdalos. I'm not on the AMYT shareholder register so I'm NOT in possession of a "shareholder pack". I realise now my post was complete nonsense. However if I make an error I own up and always admit it, unlike many who post on these bb's.
papillon
29/8/2019
13:06
Have we any idea when AMRYT is scheduled to go onto the NASDAQ?
tiananmen
29/8/2019
13:04
You are right, webpax. I've misread the RNS. I'll delete my post. It's nonsense.
papillon
29/8/2019
12:45
Can't see where it says AP101 is being 'hived off'? It looks like it's just a bonus payment if AP101 is successful to recognise early AMYT investors involvement. The drug will still be part of the AMYT portfolio and all investors will benefit going forward if it's successful.
webpax
29/8/2019
11:36
mdalos1 29 Aug '19 - 08:20 - 4753 of 4753 0 0 0 Well the huge, time consuming and far too expensive Pack for Shareholders was a challenge BUT ultimately it amounts to just a few basic things: 1) Sell out at an inevitable peak that the whole exercise is nurturing, to profit break even or reduce one's losses 2) Hold in the hope of higher highs as the whole exercise unfolds, particularly if AP101 might come to something - which is itself nothing but a 50:50 gamble at best 3) Hold and ultimately lose out on any benefits 1) or 2) might present as everything eventually comes home to roost I know what I'm going to do, now I'm availed of the fine detail. Won't be seeing you soon enough as I exit somewhere between 1) and 2) this Autumn >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Whatever you do, mdalos, I wish you ATB. The same ATB applies to any existing shareholder whatever they intend to do with their shares. Post EDITED. Nonsense deleted.
papillon
28/8/2019
15:56
I'm hoping that the US$60m placing to be priced at £1.48p (according to yesterday's RNS) means the AMYT share price will be higher that the current share price and closer to that £1.48p when it takes place. Fingers crossed as always! The fact that a non exec, Ray Stafford, has forked out £826k of his cash on buying shares in the initial placing at 90p is, in my opinion, a big vote of confidence in AMYT's future. Either that or he's taken leave of his senses as I can't imagine anyone forking out £826k unless they were either supremely confident, or as mad as a hatter! :-) I'm surprised by the lack of posts today; I'm presuming AMYT is still under the radar of most active PI's. Even Bronxville, on the lse, sounds bullish on AMYT (but not on AP101) citing the Market Cap of Krystal Biotech on Nasdaq as US$750m. Now it appears that Krystal Biotech have not much else in their locker apart from a gene therapy treatment for EB currently being trialled in phase II. AMYT of course have their own gene therapy treatment for EB, namely AP103. It lags a bit behind the competition, but some believe it to be a better bet. We shall see. A US$750m market cap for AMYT on Nasdaq would be nice (current Mkt Cap around £55m), plus AMYT will (hopefully) have other irons in the fire (namely the Aegerion treatments, Mylept and Juxtapid) . Fingers crossed as always.
papillon
Chat Pages: Latest  207  206  205  204  203  202  201  200  199  198  197  196  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200814 09:40:26